BACKGROUND: The induction and maintenance of intravenous anesthesia by propofol-TCI has been popular. When infusing propofol with other drugs at the same intravenous access line, incompatibility may result. We attempted to evaluate the incompatibilities between propofol and rocuronium by subtherapeutic dosing of rocuronium. METHODS: Eighty patients were randomized into two groups. Induction of anesthesia was done by propofol-TCI. The patients in group 1 received rocuronium 0.6 mg/kg at the same intravenous access line with propofol infusion and in group 2 received rocuronium at the different intravenous access line with propofol infusion. One Hz single twitch responses were measured by acceleromyography after rocuronium administration. Intubation was done when the twitch height depressed more than 95% of the baseline. The intubating conditions were assessed and graded as excellent, good, poor and bad. Onset time, recovery index and duration were compared between the two groups. RESULTS: The onset was significantly delayed in group 1 (124.9 +/- 35.5 vs. 101.8 +/- 22.1), but there were no significant differences in the intubating condition, recovery index, duration and the incidence of withdrawal response to rocuronium injection. CONCLUSIONS: Onset time was delayed when administrating rocuronium at the same intravenous access line with propofol-TCI. So giving rocuronium at the different intravenous access line with propofol infusion would be helpful to achieve adequate intubating condition rapidly.
Anesthesia ; Anesthesia, Intravenous ; Humans ; Incidence ; Injections, Intravenous* ; Intubation ; Propofol*

BACKGROUND: Similar to lipid emulsion propofol, microemulsion propofol also causes a high incidence of pain during intravenous injection. Various methods have been used to minimize the incidence and severity of pain on injection of lipid emulsion propofol. In this study, we investigated the effect of a lidocaine mixture on pain induced by microemulsion propofol injection, and sought to determine the optimal dose of lidocaine that could reduce pain on injecting a propofol-lidocaine mixture. METHODS: One hundred sixty (n = 160) patients of American Society of Anesthesiologists physical status class I or II were randomly allocated to four groups: Group A, control; Group B, 20 mg lidocaine; Group C, 30 mg lidocaine; Group D, 40 mg lidocaine. In each patient, pain on microemulsion propofol solution injection was graded as none, mild, moderate, or severe. RESULTS: The incidence of pain in groups A, B, C, and D was 97.5%, 80%, 65%, and 50%, respectively. Increasing the lidocaine dose significantly reduced pain (P < 0.05). One patient in Group D (2.5%) had moderate to severe pain, which was significantly lower than groups B (42.5%) and C (32.5%) (P < 0.05). CONCLUSIONS: The lidocaine and propofol mixture is effective in alleviating pain associated with microemulsion propofol injection. Within this dose range and in this patients population, increasing lidocaine dosage significantly reduced pain during injection of microemulsion propofol.
Humans ; Incidence ; Injections, Intravenous ; Lidocaine ; Propofol

The influence of the intravenous injection of single-dose diazepam on plasma potassium, sodium and chloride concentions was studied in 36 healthy patients undergoing minor surgical operations and this investigation was limited to the first 10 minutes after the intravenous injection of diazepam, 10mg. A significant decrease of plasma potassium concentration(-0.24 ~ -0.25 mEq/1) was observed with diazepam at 5 and 10 minutes but the diazepam investigated in this study did not have a significant effect on the plasma sodium and chloride.
Diazepam* ; Humans ; Injections, Intravenous* ; Plasma* ; Potassium* ; Sodium*

PURPOSE: The aim of this study was to evaluate the clinical value of rectal gas distension F-18 FDG PET/CT imaging for the differentiation of the rectal focal uptake lesions. MATERIALS AND METHODS: Twenty four patients (M:F=11:13, Age 62.8+/-12.4 years) underwent rectal gas distension F-18 FDG PET/CT, prospectively: initial image at 50-60 min after the intravenous injection of F-18 FDG and rectal distension image after the infusion of air through the anus. Focally increased uptake lesions on initial images but disappeared on rectal distension images defined a physiological uptake. For the differential evaluation of persistent focal uptake lesions on rectal distension images, colonoscopy and histopathologic examination were performed. RESULTS: Among the 24 patients, 27 lesions of focal rectal uptake were detected on initial images of F-18 FDG PET/CT. Of these, 7 lesions were able to judge with physiological uptake because the focal increased uptake disappeared from rectal distension image. Remaining 3 lesions were non-rectal lesions (2 lesions: rectovesical space, 1 lesion: uterine myoma). Among 17 lesions which was showed persistent increased uptake in rectal distension image, 15 lesions were confirmed as the malignant tumor (SUVmax=15.9+/-6.8) and 2 lesions were confirmed as the benign lesions including adenoma and inflammatory disease. CONCLUSION: The rectal distension F-18 FDG PET/CT imaging could be an important noninvasive method for the differentiation of malignant and benign focal rectal uptake lesions including physiologic uptake.
Adenoma ; Anal Canal ; Colonoscopy ; Humans ; Injections, Intravenous

An oculogyric crisis which was resolved after intravenous injection of diazepam 10 mg developed in a 16-year-old girl after an oral dose of 400 mg of albendazole. Although ocular side effects of albendazole are rare, it can induce an alarming oculogyric crisis in some sensitive subjects. The mechanism of the oculogyric crisis is unclear.
Adolescent ; Albendazole* ; Diazepam ; Female ; Humans ; Injections, Intravenous

BACKGROUND:Intravenous injection of rocuronium produces intense discomfort at the site of injection in 50?80% of conscious patients.Many trials have sought to lessen the injection pain.The present study evaluated the incidence and severity of pain associated with intravenous injection of rocuronium in conscious patients, and determined the efficacy of different doses of 50 mg rocuronium diluted in 0.9% NaCl at minimizing injection pain. METHODS:Sixty healthy patients scheduled for general anesthesia were randomly divided into three groups (n = 20 each) for injection of 10 ml (NS 10), 20 ml (NS 20), or 40 ml (NS 40) of the NaCl-diluted rocuronium. Before induction, the incidence of pain was ascertained and its severity during subsequent rocuronium injection was classified as none, mild, moderate, severe, very severe. RESULTS:The incidence and the severity of pain were significantly lower in the NS 40 group than in the NS 10 group (P< 0.05). Pain severity was mild or absent for all NS 20 and NS 40 patients. CONCLUSIONS:Rocuronium diluted with NaCl effectively reduces injection pain in a dose dependent manner. s
Androstanols ; Anesthesia, General ; Humans ; Incidence ; Injections, Intravenous

BACKGROUND:Intravenous injection of rocuronium produces intense discomfort at the site of injection in 50?80% of conscious patients.Many trials have sought to lessen the injection pain.The present study evaluated the incidence and severity of pain associated with intravenous injection of rocuronium in conscious patients, and determined the efficacy of different doses of 50 mg rocuronium diluted in 0.9% NaCl at minimizing injection pain. METHODS:Sixty healthy patients scheduled for general anesthesia were randomly divided into three groups (n = 20 each) for injection of 10 ml (NS 10), 20 ml (NS 20), or 40 ml (NS 40) of the NaCl-diluted rocuronium. Before induction, the incidence of pain was ascertained and its severity during subsequent rocuronium injection was classified as none, mild, moderate, severe, very severe. RESULTS:The incidence and the severity of pain were significantly lower in the NS 40 group than in the NS 10 group (P< 0.05). Pain severity was mild or absent for all NS 20 and NS 40 patients. CONCLUSIONS:Rocuronium diluted with NaCl effectively reduces injection pain in a dose dependent manner. s
Androstanols ; Anesthesia, General ; Humans ; Incidence ; Injections, Intravenous

PURPOSE: The purpose of this study was to identify factors that have an influence on the pain which patients recognize when receiving an intravenous injection. METHOD: Participants were 111 patients who were admitting to C University Hospital. The collected data were analyzed using the SPSS 11.0 program. RESULTS: For the participants, factors related to administration of medication were the following: Phlebitis scale, who administers the IV injection, failure to complete the IV injection, explaination of the IV injection and rate of injection. Level of pain, depression and anxiety in the participants was as follows: Pain (4.86+/-2.09), depression (35.76+/-9.91), anxiety (32.34+/-8.87). There were positive correlations between pain and depression (r= .437, p< .000), between pain and anxiety (r= .478, p< .000), and between depression and anxiety (r= .544, p< .000). CONCLUSION: Such findings provide new insights into the dynamic relationships between depression, anxiety and pain which patients recognize when having an intravenous injection. Further studies should be conducted to establish the causal relation between depression, anxiety and pain and to determine appropriate nursing interventions.
Anxiety* ; Depression* ; Humans ; Injections, Intravenous* ; Nursing ; Phlebitis

Authority estimated the concentration of fluorescein sodium in the blood, anterior chamber and vitreous after injection of 10% fluorescein sodium, 25mg/kg, according to the lapse of time. Also intravitreal fluorescein sodium concentration was measured after intravitreal injection of 0.1 % fluorescein sodium 10 micro liter according to the lapse of time. The results were as follows. 1. In the normal rabbits, the concentration of fluorescein sodium in the anterior chamber and vitreous were 159.3 +/- 101.7 X 10(-9) gm/ml and 3.6 +/- 4.7 X 10(-9) gm/ml, respectively after 1 hour of fluorescein sodium intravenous injection. The Cv/Ca was 0.02 +/- 0.028(Cv: concentration of fluorescein in the vitreous) (Ca: concentration of fluorescein in the ant. chamber). 2. After injection of sodium fluorescein in the normal rabbit, the concentration of fluorescein in the blood showed rapid decrease in logarithmic manner in the vitreous, the concentration peaked 1 hour and 2 hours after injection which persisted several hours. 3. The concentration of fluorescein sodium in the vitreous after intravitreal injection of fluorescein decreased at logarithmic rate which disappeared 24 hours after injection.
Anterior Chamber ; Ants ; Fluorescein* ; Injections, Intravenous ; Intravitreal Injections ; Pharmacokinetics* ; Rabbits

PURPOSE: Radiotracers that bind to the central benzodiazepine receptor are useful for the investigation of various neurological and psychiatric diseases. [C-11]Flumazenil, a benzodiazepine antagonist, is the most widely used radioligand for central benzodiazepine receptor imaging by PET. We synthesized 3-(2-[F- 18]fluoro)flumazenil, a new fluorine-18 (t1/2=110 min) labeled analogue of benzodiazepine receptor imaging agent, and evaluated in vivo for biodistribution in mice. MATERIALS AND METHODS: Flumazenil (Ro 15-1788) was synthesized by a modification of the reported method. Precursor of 3-(2-[F-18]fluoro)flumazenil, the tosylated flumazenil derivative was prepared by the tosylation of the ethyl ester by ditosylethane. [F-18] labeling of tosyl substitued flumazenil precursor was performed by adding F-18 ion at 85 degree C in the hot cell for 20 min. The reaction mixture was trapped by C18 cartridge, washed with 10% ethanol, and eluted by 40% ethanol. Bidistribution in mice was determined after intravenous injection. RESULTS: The total chemical yield of tosylated flumazenil derivative was ~40%. The efficiency of labeling 3-(2-[F-18]fluoro)flumazenil was 66% with a total synthesis time of 50 min. Brain uptakes of 3-(2-[F-18]fluoro)flumazenil at 10, 30, 60 min after injection, were 2.5+/-0.37, 2.2+/-0.26, 2.1+/-0.11 and blood activities were 3.7+/-0.43, 3.3+/-0.07, 3.3+/-0.09%ID/g, respectively. CONCLUSION: We synthesized a tosylated flumazenil derivative which was successfully labeled with no-carrier-added F-18 by nucleophilic substitution.
Animals ; Benzodiazepines* ; Brain ; Ethanol ; Flumazenil* ; Injections, Intravenous ; Mice ; Receptors, GABA-A*